Chemoprevention of Gastric Cancer: Non-steroidal Anti-inflammatory Drugs Including Aspirin

Choi, Kee Don

doi:2017.17.4.169

Korean J Helicobacter Up Gastrointest Res > Volume 17(4); 2017 > Article

Review

The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2017;17(4):169-174.
DOI: https://doi.org/10.7704/kjhugr.2017.17.4.169 Published online December 10, 2017.

Chemoprevention of Gastric Cancer: Non-steroidal Anti-inflammatory Drugs Including Aspirin

Kee Don Choi

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Keedon@amc.seoul.kr

위암의 화학 예방 요법: 아스피린 포함 비스테로이드 소염제

최기돈

울산대학교 의과대학 서울아산병원 소화기내과

Correspondence: Kee Don Choi,
Email: Keedon@amc.seoul.kr

Received: 2 September 2017 • Revised: 26 October 2017 • Accepted: 31 October 2017

Abstract

Many reports have been published that provide epidemiological evidence supporting the efficacy of aspirin and non-steroidal anti- inflammatory drugs (NSAIDs) in cancer prevention. The presumed mechanism of chemoprevention is inhibition of cyclooxygenase (COX)-2. Aspirin exhibits an anticancerous effect through several inter-related mechanisms: prostaglandin synthesis and catabolism in epithelial cells, inhibition of Wnt-β-catenin signaling, inactivation of platelets, and the host immune response. Several clinical studies have demonstrated that aspirin and NSAIDs exhibit chemopreventive effects in stomach cancer. However, well-designed clinical studies to answer critical clinical questions such as additional benefits of aspirin or NSAIDs after eradication of Helicobacter pylori, and the net benefit despite the adverse effects of long-term intake of aspirin or NSAIDs, are needed.

Key Words: Anti-inflammatory agents, non-steroidal; Aspirin; Chemoprevention; Stomach neoplasms